Please login to the form below

Not currently logged in
Email:
Password:

cinacalcet

This page shows the latest cinacalcet news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount. ... Specifically, it is administered three times a week as an infusion at the end of the dialysis process, while cinacalcet

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on dialysis who develop secondary hyperparathyroidism (sHPT).

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    The rejection is a big disappointment for Amgen, which had suggested that Parsabiv (also known as velcalcetide and AMG 416) could equal and potentially exceed Sensipar (cinacalcet) as a revenue driver.

  • Amgen's Sensipar follow-up clears phase III trial Amgen's Sensipar follow-up clears phase III trial

    Now, Amgen is edging close to bringing a successor to Sensipar (cinacalcet) to market after follow-up AMG 416 (formerly known as velcalcetide) met its objectives in a phase III trial

  • Amgen profits down on rising costs Amgen profits down on rising costs

    Among Amgen's other new products, Sensipar/Mimpara (cinacalcet) for hyperparathyroidism grew 19 per cent to $256m, while Xgeva and Prolia (both denosumab) for preventing bone fractures rose 72 per cent

  • Amgen buoyant as profits rise in Q3 Amgen buoyant as profits rise in Q3

    Hyperparathyroidism drug Sensipar/Mimpara (cinacalcet) had a good quarter, up 18 per cent to $243m, while colorectal cancer drug Vectibix (panitumumab) rose 11 per cent to $88m.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics